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Abstract 
 
There is great ethical debate regarding the complex area of human embryonic 
stem cell research (hESCR) because in order to access the cells, destruction of 
the embryo is required. Therefore many different opinions regarding the moral 
status of the human embryo have developed. The environment of hESCR is 
highly politicised and one of the few scientific fields that is prohibited in some 
jurisdictions. Within the EU there is a diverse legislative environment. In 
particular there is no specific legislation in Ireland despite both the Commission 
on Assisted Human Reproduction and the Irish Council for Bioethics calling for 
such legislation in 2005 and 2008 respectively. As a result scientists have had 
to develop their own policies and regulations while looking elsewhere for 
funding. The Irish Medical Council has had to draft guidelines for doctors 
highlighting the regulatory vacuum. Corporations, non-profit organisations and 
philanthropists have had to step into the regulatory and funding void created by 
governments internationally. Despite these restrictions, research in the area of 
stem cells is rapidly evolving and progressing especially in the past year with 
use of the CRISPR-Cas9 system in gene editing of human embryos. With the 
recent advances in human embryo culturing, the 14 day rule originally enacted 
in the UK's Human Fertilisation and Embryology Act in 1990 is being questioned 
with discussions for a possible extension past 14 days. There is a moral duty 
amongst the scientific and medical community to practise ethical research and 
this is especially true for hESCR but clear legislations and regulatory bodies are 
required to guide these pioneers of research through this contentious and 
provocative research.  
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Chapter 1: Introduction  
 
1.1 Introduction 
“While we must devote enormous energy to conquering disease, it is equally 
important that we pay attention to the moral concerns raised by the new frontier 
of human embryo stem cell research. Even the most noble ends do not justify 
any means.” 
George W. Bush, August 9, 2001 
 
“Today, with the Executive Order I am about to sign, we will bring the change 
that so many scientists and researchers; doctors and innovators; patients and 
loved ones have hoped for, and fought for, these past eight years: we will lift the 
ban on federal funding for promising human embryonic stem cell research.  We 
will vigorously support scientists who pursue this research.  And we will aim for 
America to lead the world in the discoveries it one day may yield.” 
President Barrack Obama, March 9, 2009 
 
Seven years on, the issues surrounding human embryonic stem cell research 
(hESCR) are immense with huge ethical, legal and political implications that 
even scientists alike cannot agree upon.  In 2010, US District Judge Royce 
Lamberth blocked President Obama's executive order, claiming that the funding 
violates a 1996 law prohibiting the use of federal funds for any research which 
involves the destruction of human embryos.1 The judge temporarily blocked all 
federal funding for hESCR. 
The landmark decision on abortion rights in 1973 by the Supreme Court, Roe v. 
Wade [410 U.S. 113] sparked controversy regarding the human embryo as the 
decision reshaped politics and divided society into pro-life and pro-choice 
groups.2 During the Reagan and Bush administration, funding was not available 
for hESCR culminating in the 1995 Dickey-Wicker amendment that banned 
federal funding of such research.3 The second Bush administration banned 
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federal funding again in 2001 primarily the National Institutes of Health (NIH)) 
that had been allowed under the Clinton administration. The ban exempted 
research on the few hESC lines that had already been created.4 Some States 
as a result created state funding initiatives to support hESC R. In 2004 the 
California Institute for Regenerative Medicine (CIRM) was funded from $3 billion 
state bonds enabled through a ballot – Proposition 71.5 Despite ongoing legal 
disputes6 the Obama administration lifted the Bush ban and enabled federal 
funding for research on hESC lines created after 2001. In contrast, hESCR has 
not been controversial in Sweden7 even though opposition and regulatory 
restrictions exist at the level of the European Union. 
Time magazine have dubbed the "complexity and drama" surrounding these 
cells as the "Great Debate". An example of this occurred in China in 2015 
where a gene in the human zygote was cleaved using genome editing tools.8 
Reactions to this ground breaking news were mixed amongst the scientific 
community.  
“In the wake of the first ever report that scientists have edited the genomes of 
human embryos, experts cannot agree on whether the work was ethical. They 
also disagree over how close the methods are to being an option for treating 
disease.” — Nature News, April 2015.  
The team submitted its work to both Science and Nature initially but both 
journals rejected the manuscript on ethical grounds, probably anticipating media 
controversy.9 The fact that the paper was accepted by the journal Protein and 
Cell, which is partially owned by the Chinese government, within two days of 
submission raised some concerns too.  
As part of my training as an oncologist, I spent two years working in a laboratory 
undertaking cancer research on an aggressive subtype of breast cancer, triple 
negative breast cancer (TNBC). During that time I performed hundreds of in 
vitro experiments using five different TNBC cell lines originally taken from five 
women over the past few decades.   
Cell lines are “immortal”. They can grow indefinitely, be frozen for decades, 
divided into different batches and shared among scientists.10 Like the thousands 
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of cell lines that are grown every day in laboratories worldwide, my five cell lines 
were well established in the cancer research arena. I never questioned that and 
essentially took the whole process for granted. The cell lines were purchased 
from the well-recognised international company, ATCC® (American Type 
Culture Collection) an independent, private, non-profit biological resource centre 
and research organization that adhere to the highest ethical standards obtaining 
cell lines. 
However while researching the ethics for obtaining cancer cell lines I came 
across the history of the HeLa cells which is an extremely common type of 
cervical cancer cell line used in research today and invaluable to medical 
research. The method in which this cell line was discovered and originally used, 
demonstrates how different medical practice and ethics were 60 years ago in 
terms of patient consent, confidentiality and also how the paternalistic patient-
doctor relationship was the norm.  
In 1951, George Otto Gey a scientist at Johns Hopkins Hospital in Baltimore, 
Maryland, created the first immortal human cell line with a tissue sample taken 
from a young African American woman with cervical cancer, Henrietta Lacks, 
which became the HeLa cell line.10 She was a tobacco farmer from southern 
Virginia who developed cervical cancer age 30 and died a year later from the 
disease. A doctor at Johns Hopkins took a piece of her tumour without her 
knowledge or consent during a vaginal examination. He gave the biopsy to the 
scientist Otto Gey who had been trying to grow tissues in culture for decades 
without success.10  
Henrietta’s cells were the first immortal human cells ever grown in culture.10 
They were essential to developing the polio vaccine in 1954 and were the first 
human cell line successfully cloned in 1955.11 Many scientific landmarks have 
used her cells including gene mapping with German researchers publishing the 
DNA code in 2013 and in vitro fertilisation.12 HeLa cells were the first human 
biological materials ever bought and sold, which helped launch a multi-billion-
dollar industry with 11,000 patents involving HeLa cells.10 However neither she 
nor her family gave permission to use her cells and until recently she was not 
recognised or acknowledged for the contribution to research. 
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In August 2013, an agreement by the family and the National Institutes of 
Health (NIH) was announced that gave the family some control over access to 
the cells' DNA code and a promise of acknowledgement in scientific papers.12 In 
addition, two family members joined a six-member committee which will 
regulate access to the code. Medical ethicists praised the NIH action because 
there was no legal obligation to give the family any control over access to the 
genetic data. In March 2015, Baltimore Mayor Stephanie Rawlings-Blake 
honoured the memory of Henrietta Lacks delivering a speech emphasising race 
and ethics in medicine.13  
Figure 1.1 is a timeline of the history of research using human subjects 
highlighting the establishment of the HeLa Genome Data Access working group 
in 2013 by the NIH acknowledging Henrietta Lacks and her family. 
Purchasing adult cell lines for in vitro research involves strict and 
straightforward regulations that researchers are easily able to understand and 
follow. The more controversial hESCR is fraught with no clear or uniform legal 
guidelines internationally resulting in a huge lack of public funding, therefore 
compromising researchers and the potential for future medical advances to cure 
diseases.  
My thesis will focus on the moral and legal status of the human embryo in terms 
of stem cell research comparing and contrasting Ireland’s legal vacuum with 
other countries and regulatory bodies in chapter 2. The current Irish Medical 
Council guidelines for doctors will be discussed specifically to Assisted Human 
Reproduction (AHR) and hESCR in chapter 2. Current advances in research in 
particular mitochondrial replacement therapy and the very topical gene editing 
technology such as clustered regularly interspaced short palindromic repeat 
(CRISPR) which has taken centre stage over the past year will be reviewed in 
chapter 3. Chapter 4 will concentrate on alternative sources of stem cells such 
as adult tissue stem cells and the reprogramming techniques such as seen in  
induced pluripotent stem cells (iPSCs) focusing specifically on the similarities 
between embryonic and cancer stem cells . 
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1.2 Stem Cells Defined 
Stem cells are immature cells with regenerative potential from which all 
specialised tissue is derived.14 They are more potent in the fetus. The main 
types are embryonic, fetal and adult stem cells.  
Embryonic stem cells are developed from a female egg after it is fertilized by 
sperm, a process that takes 4-5 days. Embryogenesis spans from the end of 
fertilisation (zygote stage) until the end of the eighth week of development, after 
which the developing human is referred to as a fetus.14  
The cells of the early embryo (day 1-4) are totipotent embryonic stem cells and 
have the potential to develop into different cell types that make up the human 
body including the placenta.14 Only embryonic stem cells of the morula are 
totipotent. 
On day 5 of embryogenesis the embryo develops into a blastocyst from which 
the embryoblast or inner cell mass arises.14 This inner cell mass is the source of 
embryonic stem cells and in order to access these cells, destruction of the 
blastocyst must occur. At this point, the stem cells are pluripotent and will give 
rise to all of the different types of cells of the developing embryo except the 
placenta. Embryonic stem cells can, therefore, be either totipotent or 
pluripotent, depending on the stage of developing embryo from which they are 
isolated.14 This is in contrast to fetal and adult stem cells which are mainly 
multipotent specialising into the different cell types of their tissue of origin.  
Figure 1.2 is a schematic representation of embryogenesis demonstrating the 
pluripotent stem cells of the blastocyst in contrast to the totipotent cells of the 
morula. 
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Figure 1.2:- Embryogenesis; Stem cells extracted from the inner cell mass of the blastocyst are 
pluripotent and can differentiate into any cell type of the body such as cells for the circulatory, 
nervous or immune system. 
 
Supernumerary IVF embryos are the main source of human embryonic stem 
cells for research which involves destruction of the human embryo by removing 
stem cells from the embryo at the blastocyst stage.6 In the UK, the cut-off date 
for embryonic research is 14 days after conception, or around the time of 
implantation.7 
Stem cell research can potentially help treat a range of medical diseases. 
Studying the behaviour of these cells advances our knowledge of basic 
mechanisms of cell biology and embryonic development.14 Support for hESCR 
arises from the moral imperative to develop promising therapies for unmet 
medical needs benefitting society as a whole and the potential for economic 
progression.2  
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1.3 The Moral Status of the Embryo 
The destruction of a human embryo is required to carry out embryonic stem cell 
research raising serious ethical concerns and debate. The lack of defined 
legislation is due to the different views regarding the moral status of the embryo. 
“The moral status an individual would personally attribute to embryos is, 
therefore, likely to determine the level of legal protection that individuals would 
envisage granting them and is at the core of the ethical debate relating to stem 
cell research.”14   
hESCR forces us to choose between two important moral principles or duties: 
respecting human life and alleviating suffering. In order to carry out this type of 
research we must destroy the embryo, a potential human life. What decides 
between these two moral principles is our opinion of the status of an embryo. 
Should it have the same status as a human at all? To have moral status is to 
deserve some of the protections afforded by social norms.15 Moral principles 
should be applied based on the properties of the being. The five prominent 
theories of moral status identify one or more properties needed to acquire moral 
status.15 
1) Theory based on Human Properties - all humans have full moral status 
including a human embryo which is a member of the species Homo 
sapiens in the earliest stage. Even though hESCR could potentially 
eradicate diseases and thus be interpreted as a good result, embryos 
should not be used as means to an end, even if is a positive end.15  
2) Theory based on Cognitive Properties – individuals have moral status 
because of their cognitive capacities. This theory does not morally 
protect vulnerable individuals but in fact reduces their moral status.15 
3) Theory based on Moral Agency – the capacity to act as a moral agent 
differentiating between right and wrong. This theory is counterintuitive as 
vulnerable individuals lack moral status in this theory.15 
4) Theory based on Sentience – capacity of sentience consciousness in the 
form of feeling. Theory does not include early stage embryo or patients 
severely brain damaged.15 
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5) Theory based on Relationships – relationships that establish roles and 
obligations account for moral status. The status of the fetus is much 
stronger at term and weaker as an embryo. Only social bonds and 
special relationships determine moral status.15 
 
“A more expansive view of the moral status of nature can help us see beyond 
the stark dualism between persons and things.”16 The primary problem with the 
equal moral status view of the human embryo is this deep assumption that the 
moral universe is divided in binary terms but this dualism is overdrawn.16  
Whenever discussing the moral status the concept of “personhood” arises.14 
This concept requires a person to have a certain degree of capacity for 
rationality and self-consciousness. The capacity of sentience is also included by 
some philosophers however it is clear by the criteria that defines personhood 
the blastocyst does not qualify for personhood.  The opposite argument is that 
destroying an embryo is akin to killing a person because the personhood begins 
with the embryo.14 An embryo is a human being in the embryonic stage just as a 
teenager is a human in adolescence. Because an embryo will become a 
person, it should be treated with the same respect and given the status. There 
are also views that the embryo is not a potential life but rather a life with a 
potential and represent a human being at the earliest stages of its development 
which would be in keeping with the equal status viewpoint.16 
Potentiality is also referred to in relation to moral status as the embryo has the 
potential to develop into a human. However “there is a serious logical flaw in 
according rights to individuals based on their potential.”14 This is faulty 
reasoning. For every live birth, up to five embryos will miscarry which weakens 
the potentiality argument. “The fact that all persons were once blastocysts does 
not prove that all blastocysts are persons.”16    
Importantly there is a difference between the potentialities of an embryo in vitro 
versus in utero. Every embryo used for IVF does not develop into a full term 
pregnancy and an embryo cannot develop into a person without implantation 
into a uterus. Therefore just because an embryo has the potential to become a 
person, doesn’t mean it is a person.  
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Prior to an embryo developing a primitive steak i.e. immature nervous system at 
around 14 days, the embryo arguably has no senses because it has no central 
nervous system. Therefore if we can harvest organs from patients who are 
clinically brain dead, should we not then be able to perform experiments on 
embryos that haven’t even started to develop a nervous system? 
Using the surplus embryos that were initially created for IVF for research should 
not be considered immoral because they will have to be destroyed anyway. If 
we can utilise them for some good, then they will not have gone to waste. 
Already IVF is commonplace without degradation of human life values in 
society, our values are still regarded as the same. It is unlikely that using 
surplus embryos for research will result in society caring less about the value of 
life.   
However vulnerable populations require additional protection in biomedical 
research arising from concerns about exploitation and the inability to consent.15 
Experimenting on embryos could be considered equivalent to experimenting on 
vulnerable populations without their consent. In light of the use of vulnerable 
populations for research and the controversies associated with it, a view of full 
prohibition of the practice can be taken. Some might agree with a policy of full 
permissibility in reference to ESCR or a policy of partial permissibility. 
Despite these theories, one does not have to regard an embryo as a full human 
person to believe that it is due a certain respect. There is no biologically 
determined moment when human life acquires the moral status of a person. 
The process is gradual. The Irish Council for Bioethics adopts a gradualist 
position, granting significant moral value rather than full moral status to human 
embryos. “The moral value they are seen to possess is based on recognition of 
their potential to develop into persons, as well as the value they derive from 
representing human life in its earliest stages.”14 
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1.4 The Embryo, Fetus and Stem cells – current research and medical 
developments 
1.4.1 Stemness, cancer and cancer stem cells 
Cancer cells have the ability to bypass programmed cell death and in turn grow 
indefinitely.  As a result of this cancer cells and stem cells may have common 
underlying mechanisms. Detailed gene expression maps have now shown the 
diversity and distinctiveness in gene expression programs associated with 
stemness in embryonic and adult stem cells.17 There is a shared transcriptional 
program in embryonic stem cells and cancer stem cells. Activation of an ESC-
like gene expression program in adult epithelial cells can reprogram the cells 
into cancer stem cells and achieve pathologic self-renewal.17 The ability to 
create induced cancer stem cells may provide opportunities to better define the 
biology of cancer stem cells. 
1.4.2 Mitochondrial DNA 
An international team led by researchers at the Salk Institute for Biological 
Studies in La Jolla, California, published results in Cell last month of a method 
developed to selectively remove mutated mitochondrial DNA from the murine 
germline and single-celled mouse embryos.18 The scientists hope to offer the 
technique as an alternative to mitochondrial replacement therapy—a procedure 
also known as “three-parent IVF” that was recently green-lighted by the U.K. 
parliament. 
1.4.3 Induced Pluripotent Stem Cells 
In 2006, Takahashi and Yamanaka showed that differentiated fibroblasts from 
mice could be reprogrammed into stem cells.19 These induced pluripotent stem 
cells (iPSC) have the potential to form any of the three embryonic cell types, 
endoderm, mesoderm, or ectoderm.19 
However iPSC are unable provide information about the mechanisms of early 
human embryogenesis in contrast to ESC. The weight of scientific opinion is 
that iPSC cells should not replace but complement ESC technology. 
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1.4.4 Fetal Surgery 
The first successful fetal surgery, a blood transfusion was performed in 1963 in 
New Zealand to counteract the effects of haemolytic anaemia, or Rh disease, 
on a fetus.20 
Fetal surgery is rare and the option exists for only a small number of pregnant 
women, as many conditions such as risk to mother and/or fetus must be met 
before fetal surgery is considered. Examples include repair of a diaphragmatic 
hernias, whereby surgeons in utero repair the muscle that divides the 
abdominal and thoracic cavities of fetuses to facilitate proper fetal lung 
development. Surgeons have also succeeded in correcting myelomeningocele, 
a type of spina bifida, by closing the tissue over the fetus’s spinal cord in the 
affected area.21 
In 2012 surgeons at Jackson Memorial Hospital, Miami successfully removed a 
rare tumour namely an oral teratoma from a fetus for the first time through in 
utero surgery.22 The tumour which occurs in 1 in 100,000 was detected at a 
routine neonatal ultrasound at 17 weeks gestation and if allowed to continue to 
grow could result in fetal haemorrhage. The mother only required local 
anaesthesia for the procedure. 
In Ireland, Professor Fergal Malone Consultant Obstetrician in the Rotunda 
Hospital performed the first radical in utero procedure in January 2007 on a twin 
pregnancy with twin-to-twin transfusion syndrome (TTTS) where abnormal 
blood vessels in the placenta within the womb transfuse too much blood into 
one baby, while the other baby is left with too little blood, leading to the death of 
both babies in nearly 100% of cases if left untreated.23 
The relationship between the pregnant woman and fetus offers a clinically 
complex situation for moral decision-making.24 Beneficence for the fetus does 
not necessarily allow for non-maleficence for the pregnant woman and vice 
versa. There is no consensus agreement on the moral status of a fetus and 
therefore the treatment of the fetus can be questioned clinically, socially, 
culturally, politically, legally, and ethically.24 
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1.5 Discussion 
The concept of the moral status of the embryo will vary across society 
depending on culture, teachings, religion and politics. A general consensus is 
not possible. If policy makers adopt one moral viewpoint which can be easily 
discarded by other members of society they risk alienating people who have a 
completely different opinion.  
In 2011, the Court of Justice of the European Union banned the patenting of 
inventions derived from human eggs or their equivalent on the basis that they 
were human embryos, the commercial exploitation of which "would be contrary 
to… morality." However this message implies that scientists engaged in stem 
cell research are immoral. Furthermore using patent law to elevate the status of 
the embryo threatens research that might benefit the health of millions.25  
In 2014 in the UK a decision by the Patent Office that unfertilised human eggs 
that have been stimulated to divide should be included in the term 'human 
embryos' was challenged in the High Court by the International Stem Cell 
Corporation.25 The High Court was advised by the Court of Justice of the 
European Union to reject part of the decision by the Advocate General. 
The U.S. Court of Appeals of the District of Colombia Circuit ruled in 2011 that 
the U.S. National Institutes of Health (NIH) can use federal money to fund 
research involving hESC overturning the preliminary injunction in the case 
Sherley v. Sebelius that prohibited the funding of human embryonic stem cell 
research. The decision was upheld again in court in 2012. 
However, the legal situation in the USA is evolving depending on state. In 2011, 
the states of Minnesota and Oklahoma proposed a legislation to criminalise 
certain embryonic stem cell research procedures despite concerns expressed 
over the commercial impact of these Bills. An amendment to the Bill was put 
forward to allow discarded embryos to be used in research was rejected. 
Identifying if a particular society is conservative or liberal helps focuses the 
discussion of the moral status and guides policy makers. In a democratic 
society, an open deliberation of the issue should be adopted and debated in a 
focused manner.26 The National Bioethics Advisory Commission stated:  
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“Although many of the issues remain contested on moral grounds, they co-exist 
within a broad area of consensus upon which public policy can be 
constructed.”27 
1.6 Conclusion 
The embryo in vitro does not have constitutional protection under article 40.3.0 
of the Irish Constitution and along with the absence of an open and transparent 
stem cell policy the moral value of the human embryo is undermined.28 Irish 
stem cell research needs a strong, transparent ethical and legislative structure 
because at present valuable international research opportunities are being 
missed because researchers cannot work effectively in an environment where 
there is no regulatory framework. 
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Chapter 2: The Legal Status of 
Human Embryonic Stem Cell 
Research  
 
2.1 Introduction 
The legal status of the embryo is not clearly defined or unified nationally and 
internationally because of differences in legal and political structures, cultures 
and religions.1 These factors ultimately impact on potential research 
opportunities while also exposing scientists who are forced to self-regulate and 
undertake such research because funding is sought from elsewhere due to the 
lack of legislation and national policy. Ireland currently provides assisted human 
reproduction (AHR) services without legislation or a regulatory framework, in 
contrast to the rest of the EU.2 With no public policy and funding in Ireland or 
indeed no form of regulatory body imposing limitations, there is a financial and 
psychological burden on patients. Because of this lack of clarity, there is an 
obvious legal and ethical dilemma. “Government inaction is exposing families to 
distress, uncertainty and protracted and expensive litigation”.3  
Legal regimes that govern hESCR may be broadly characterized as1:  
a) permissive - enabling the creation of embryos for hESCR research e.g. 
UK, Sweden, Spain, Portugal, Israel, Japan, and Australia. 
b) intermediate - placing restrictions on the derivation of embryos for 
hESCR e.g. France, USA, Canada, China, India, Turkey, Iran. 
c) restrictive - prohibiting hESCR or derivation by limiting it to imported 
hESC lines e.g. Italy, Germany, Austria, Lithuania, and Tunisia. 
d) jurisdictions that have no specific legislation in place e.g. Ireland, 
Thailand, and Colombia.  
Within the EU there is clearly a diverse legislative environment similar to the 
federated US where national and state laws overlap but also contrast in policy 
restrictions and permissions.  
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Sweden is considered liberal in terms of its hESCR policy and funding however 
it is comprehensively regulated since the Activities Involving Human Eggs for 
Research or Treatment Purposes Act 1991 was enacted.4 Similar to the UK, 
stem cells surplus embryos that were originally created for IVF can be used for 
research up to 14 days at which point they must be destroyed. In 2001 
therapeutic cloning for research purposes was enabled by the Act of Genetic 
Integrity however application for such research must be made to an ethics 
committee with approval by the donors.4 Reproductive cloning is banned. The 
Biobanks in Medical Care Act set up a national stem cell bank in 2002 to 
accommodate the increasing demand and promoting such research.4 
This is in stark contrast to Germany where the human embryo is protected 
under the German Constitution and such research is tightly governed by the 
Embryo Protection Act 1991.4 The derivation of a human embryonic stem cell 
line is considered a criminal offense. In 2002, the Stem Cell Act permitted the 
importation of stem cells for research but only cells that were created prior to 
January 2002 could be imported.5 The cut off limit was extended to May 2007 in 
2008 after pressure from scientists.6 
Religious traditions also influence public policy debate as evident in our 
Constitution with the 8th Amendment.  Amongst the Islamic faith, Iran, Turkey 
and Tunisia are the only countries to have adopted a national policy on 
hESCR.7 Iran and Turkey both have an intermediate flexible policy compared to 
a very restrictive Tunisia.7 Indeed a 'stem cell fatwa' was issued in Iran 
encouraging hESCR by the Muslim cleric Ayatollah Khamenei, the Supreme 
Leader of Iran who regularly makes the top 20 Forbes most powerful people in 
the world.8 This positive fatwa highlights Iran’s promotion of novel scientific 
research by clerics and politician possibly in an attempt to enhance the 
country's international status.7  
Iran became the first Muslim country to create hESCs from a human 
blastocyst.9 Tunisia on the other hand has banned research on hESCs entirely 
with only use in IVF.10  
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“The environment of hESCR is highly politicised and one of the few scientific 
fields that is prohibited in some jurisdictions with other notable examples being 
human germline modification.”1  
The legal status of the embryo within the EU is not completely straightforward or 
coherent which was highlighted by the European Court of Human Rights 
judgement regarding the Italian case of Parillo versus Italy [2015] in August 
2015.11 The courts ruled that Italy’s law was in fact not in conflict with Article 8 
of the European Convention on Human Rights, on the right to respect for private 
and family life.11   
Italy’s law 40, dating from February 2004 prohibits the use of human embryos 
for any research and bans the donation and destruction of human embryos for 
research.12 Despite a failed attempt of a referendum in 2005 to revisit this law 
and several appeals cases, the law was still upheld with a 2009 Ministerial 
Decree confining research to adult stem cells only and again in 2015 in the 
Parillo case.13 The argument that the law violated the right to privacy or private 
property was rejected by the European Court by 16 to 1.14 The court 
emphasised that on one hand human embryos should never be considered 
goods. But on the other hand, the court did not actually clarify whether human 
embryos should be considered a person either acknowledging the lack of 
consensus in Europe and internationally on the issue.15 
The lack of clarity in the law does not benefit scientists and the gap between in 
vivo and in vitro is narrowing with the recent successful growth of human 
embryos up to 13 days in vitro. This breakthrough, published in Nature and 
Nature Cell Biology in May16,17, has led calls to revisit the current 14 day rule 
that was originally enacted in the UK's Human Fertilisation and Embryology Act 
1990 because it is becoming increasingly evident that with improvements in 
culturing technique, it will be possible to grow human embryos beyond 14 days.  
The 14-day rule was first suggested in the UK in 1984 by the Warnock Report 
which has formed the basis of the 1990 Human Fertilisation and Embryology 
Act.18 The committee who wrote the report concluded that the human embryo 
should be respected deserving of a special status in society but to allow for 
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hESCR under tight regulation. They proposed the development of a regulatory 
body which would become the Human Fertilisation Embryology Authority. 
The reason for the 14 day rule is because at this point, twinning is no longer 
possible and it is believed by many as a result individuality is assigned at this 
stage.19 Also the 3 primitive embryonic layers are formed at around this stage 
and the subsequent development of the primitive streak i.e. the nervous system 
makes scientists very uncomfortable to carry out research on an embryo after 
14 days.20  
However this opinion is divided. This Warnock report is 32 years old with 
medical technology advancing so much since then including IVF techniques and 
gene editing. “Given the potential benefits of new research in infertility, 
improving assisted conception methods and in early miscarriage and disorders 
of pregnancy, there may be a case in the future to reconsider this law”.21 
Indeed, Sir Robert Edwards, one of the pioneers of IVF, suggested that the limit 
should be 21 days because development of cardiac cells and thus a heartbeat 
occurs around this time which is audible on the fetal ultrasound scan. 
Performing research on a fetus at this point would be considered unethical by 
many scientists. However, re-addressing this law in Parliament could result in a 
move backwards by conservative politicians and leaving well enough alone is 
an opinion adopted by some UK scientists.  
Despite the diverse legislative environment, there is an International Stem Cell 
Registry that has over 1000 human embryonic stem cell lines.22 In January 
2009, the United States Food and Drug Administration approved clinical trials 
for human embryonic stem cell therapy and there are currently 14 clinical trials 
registered in a US database (www.clinicaltrials.gov) primarily focusing on 
macular degeneration.23 The eye is a privileged site for transplantation since it 
is largely protected from immune attack. Following this, two months later 
President Barack Obama signed an executive order reversing federal 
opposition to embryonic stem cell research.24  
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2.2 The legal status in Ireland 
In Ireland there is no national policy on human embryonic stem cell research 
despite the Supreme Court ruling of the case Roche vs Roche [2009] IESC 82 
that the life of the unborn under Article 40.3.3 of the Irish Constitution does not 
include the embryo in vitro.25,26 Under current Irish law there is also no legal 
constraint on the importation and use of human embryonic stem cells in 
research.26 Ireland remains one of the only countries in Europe which has not 
introduced specific legislation assisted human reproduction.4 This has resulted 
in a regulatory vacuum, which has significant consequences not only for 
individuals using these treatments, but also for the fertility clinics themselves 
and for the general public who have a legitimate expectation that all practice 
and human embryonic research is regulated and carefully monitored. 
In 2003 the Taoiseach, Mr Bertie Ahern cast his doubts over whether Irish law 
actually prohibited human embryonic stem-cell research at all in the State and 
that there may in fact be no protection in Irish law against such research being 
carried out. This contradicts the common view that the constitutional protection 
of the life of the unborn would prohibit such work taking place. This is significant 
because it highlighted the defects present in Irish law with absolutely no 
statutory prohibition on hESCR. 
To date, protection against hESCR in this State has come from the Irish Medical 
Council guidelines for the medical profession which previously has held such 
work as unethical but more recently has adapted to specify the creation of 
embryos for the sole purpose of research as unethical.27  
Our Clinical Trials and Drugs Acts of 1987 and 1990 do not apply to human 
embryonic stem cell research. In April 2005, the Report of the Government-
appointed Commission on Assisted Human Reproduction (CAHR) was 
presented to the Government.25 The CAHR states that human embryos can 
indeed be donated for research purposes but under tight regulations and 
emphasising that human embryos cannot be created for research purposes. 
The Human Fertilisation and Embryology Authority (HFEA) is the regulatory 
body in the UK allowing research on created embryos. This is in contrast to 
Ireland which has no regulatory body. A bill introduced in the Irish parliament in 
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2008 aimed to ban embryo research in Ireland with criminal penalties but was 
never passed into law. Two other bills, including the Human Tissues Bill 2008, 
that sought to regulate the use, storage and removal of human tissue and 
materials similarly never became law.28,29  
The Programme for Government 2011 included the following paragraph on 
Bioethics:  
“We will legislate to clarify the law surrounding assisted human reproduction 
including the law relating parental relationships arising from assisted human 
reproduction. We will legislate to regulate stem cell research.”30 This has not 
materialised yet. 
There are Directives that set common safety and quality standards for human 
tissues and cells across the EU, including human eggs and sperm.31,32 The 
Directives which were incorporated into Irish law in 2006 and 2007 are 
regulated by the Health Products Regulatory Authority (HPRA) and set 
standards for donation, procurement and testing, processing, preservation, 
storage and distribution.32 However the general accepted view is that the 
Directives do not apply to tissues and cells being used in research. 
Paragraph 11 of the preamble to Directive 2004/23/EC provides as follows:- 
“This Directive does not cover research using human tissues and cells, such as 
when used for purposes other than application to the human body such as in 
vitro research or in animal models. Only those cells and tissues that in clinical 
trials are applied to the human body should comply with the quality and safety 
standards laid down in this Directive.”32 
The interpretation of Article 40.3.3 and the meaning of “the unborn” has been 
clarified not only by the High Court in the Judgement of Mr Justice McGovern in 
the case of Roche V Roche [2006] IEHC 359 delivered in November 2006 but 
also by the Supreme Court and its Judgements on the Appeal from the High 
Court [2009] IESC 82 delivered in December 2009.33,34 
The High Court concluded that there was no evidence that it was ever in the 
mind of the people voting on the 8th amendment to the constitution that 
“unborn” meant anything other than a fetus or child within the womb, and on 
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that basis it could not be concluded that embryos outside the womb or in vitro 
fell within the scope of Article 40.3.3.33 
The Attorney General submitted to the Supreme Court that the frozen embryos 
do not constitute the “unborn” within the meaning of Article 40.3.3 of the 
Constitution.34 
Irish universities have been forced to develop their own “in-house” guidelines 
permitting the use of human embryonic stem cell lines in the absence of a 
national regulatory framework. However despite the Irish Medical Councils 
original view in the 2003 guidelines, human embryonic stem cell research has 
being carried out in national university affiliated research centres such as in 
University College Cork since 2008.35 UCC’s governing body voted in favour of 
hESCR in 2008 under strict guidelines of the University Research Ethics Board 
using imported hESCs from approved jurisdictions.   
The UCD Research Ethics Committee Working Group on Regenerative 
Medicine & Research issued a Report and Recommendations in 2011. This 
report reaffirms that the use of human adult stem cells in research should be 
permitted and encouraged, providing that the current established legal and 
ethical safeguards in relation to use of human tissues are observed.35 
Science Foundation Ireland (SFI) the national foundation for investment in 
scientific and engineering research does not supply funding for ESCR. 
“Pending legislation from the Department of Health and Children governing 
assisted human reproduction and related practices, and in line with a current 
directive from the Department of Enterprise, Trade and Innovation, SFI is not in 
a position to fund research using human embryonic stem cells.”36  
In 2012, the Irish Stem Cell Foundation hosted its second conference, the Irish 
Stem Cell Summit, in Dublin. The Summit focused on the underdevelopment of 
Irish policy and law pertaining to stem cells, and the detrimental effect this has 
on the quality of research in the area, as well as the harm this is doing to public 
trust, international investment and collaboration.37 
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In 2014 a European coalition of scientific societies, including the Irish Stem Cell 
Foundation called on the European Commission and European Parliament to 
maintain current plans for spending on stem cell research under the EU's new 
research programme, Horizon 2020 allowing research using all forms of stem 
cells, subject to meeting fundamental ethical principles.38 
In February 2015 the Department of Health held a press release announcing 
the Governments plans to legislate for assisted human reproduction and 
associated research. “The Government has agreed to prepare new laws to 
regulate surrogacy and the broader area of assisted human reproduction and 
associated research, and bring to an end the legal uncertainty in which these 
services currently operate.”2  
However eleven years ago the Commission on Assisted Human Reproduction 
called for such legislation as did the Irish Council for Bioethics in 2008.25,39 The 
specific proposals in the draft Heads of the Bill include that human embryos can 
be donated for research, human embryonic stem cell research should be 
permitted in certain cases but the creation of embryos for research and other 
experimental practices will be prohibited.2 The Minister also proposed that the 
State cover the costs of fertility treatments. 
Also worth mentioning sex selection for gender balancing will be banned. 
However, in cases where there is a high risk of serious genetic disease or 
impairment, sex selection for medical reasons will be permitted subject to strict 
criteria 
Prior to the change of government in February the former Health Minister Dr 
Leo Varadkar announced the draft General Scheme of a Bill for assisted human 
reproduction would be published in the summer. New Health Minister Simon 
Harris stated on 31st May that the draft General Scheme is yet to be completed 
and once done the Department of Health “will conduct a widespread 
consultation on the document during which stakeholders and members of the 
public will be invited to share their views. In addition, the General Scheme will 
be submitted to the Joint Oireachtas Committee on Health and Children for pre-
legislative scrutiny.”40  
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Given the pace at which the Government is addressing repealing the 8th 
Amendment, it is unlikely that we will see a new legislation on AHR this year. 
On the 27th July, an Taoiseach announced Supreme Court Judge Mary Laffoy 
will chair the citizen’s assembly due to take place shortly with the 8th 
Amendment the first item to be discussed.41 Conclusions thereafter will be 
forwarded to the Oireachtas committee before any decision for a referendum is 
made. Given the strong Catholic influence that is still evident in Irish society 
today regarding conception and the equal status of the embryo, removing the 
8th amendment from our Constitution will be a slow process with much 
contentious debate.  
The Government and public are still fiercely divided in Ireland on issues 
surrounding the embryo and the fetus. This was demonstrated by two recent 
events that occurred involving the Government. The first being the fatal fetal 
abnormalities Bill that was defeated in the Dáil on the 7th July as it was deemed 
unconstitutional.42 This was despite the UN Human Rights Committee calling for 
the prohibition of abortion in Ireland to be reversed the previous month in June 
as it violates the UN Covenant on Civil and Political Rights stating the "The 
State party should amend its law on voluntary termination of pregnancy, 
including if necessary its Constitution, to ensure compliance with the Covenant, 
including effective, timely and accessible procedures for pregnancy termination 
in Ireland, and take measures to ensure that healthcare providers are in a 
position to supply full information on safe abortion services without fearing being 
subjected to criminal sanctions." Unsurprisingly there was a mixed reaction in 
Ireland to this UN report with the Pro Life Campaign calling the UN a “de facto 
lobby group for abortion”43  
When it comes to ESCR we clearly lack a strong, transparent, ethical and 
legislative structure. Ireland needs to be progressive regarding this matter 
because at present valuable international research opportunities are being 
missed because researchers cannot work effectively in an environment where 
there is no regulatory framework. 
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2.3 Irish Medical Council Guidelines of hESCR  
Scientists are bound by the policies of their organisation in contrast to medical 
doctors performing in vitro experiments who are bound by the Medical Council 
Regulations in the country where the research is being carried out. 
In 2003 the Council published the 6th 'Guide to Professional Conduct and 
Ethics for Registered Medical Practitioners' in collaboration with the Irish 
Council for Bioethics for discussions on ethics and the human embryo.  
However, the 7th Edition which was issued by the Medical Council in November 
2009 differs substantially from the earlier 6th Edition with regard to the issue of 
assisted human reproduction. 
The original Section F entitled ‘Genetic Testing and Reproductive Medicine’ 
which was present in the 6th Edition was removed entirely. In particular; 
Section 24.1 “In a rapidly evolving and complex area, doctors are reminded of 
their obligation to preserve life and to promote health. The creation of new 
forms of life for experimental purposes or the deliberate and intentional 
destruction of in vitro human life already formed is professional misconduct.” 
Section 24.5 “Techniques such as I.V.F. should only be used after thorough 
investigation has failed to reveal a treatable cause for the infertility. Prior to 
fertilization of an ovum, extensive discussion and counselling is essential. Any 
fertilised ovum must be used for normal implantation and must not be 
deliberately destroyed.” 
This entire Section F has now been removed and replaced with a new section 
entitled “Assisted Human Reproduction” which does not discuss genetic testing 
at all. The updated 8th Edition guidelines have recently been released with a 
copy only posted to doctors July 2016 maintaining the section: 
Section 47.1 “Assisted human reproduction treatments, such as In Vitro 
Fertilisation (IVF), should only be used after thorough investigation has shown 
that no other treatment is likely to be effective. You must ensure that 
appropriate counselling has been offered to patients and that the patients have 
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had adequate time to consider the information provided before giving informed 
consent to any treatment.” 
“A fertilised ovum must not be deliberately destroyed” from the 6th Edition has 
been removed but not replaced with any clear alternative guidelines in either the 
7th or 8th Editions. Also the previous phrase “The creation of new forms of life 
for experimental purposes or deliberate destruction is professional misconduct” 
has been removed entirely. Section 47.4 now states “you must not take part in 
the creation of new forms of life solely for experimental purposes. You must not 
engage in human reproductive cloning.” This implies that destruction of an 
ovum is now permissible and not considered professional misconduct anymore. 
The use of surplus embryos originally created for IVF is also not discussed 
which can be interpreted as a go ahead in research and experimentation.  
The Medical Council recognizes that, in the absence of legislation in this area, 
there is a need for further guidelines on assisted human reproduction. It is also 
noteworthy that these Guidelines apply to medical clinicians only and not 
scientific researchers. 
2.4 Funding sources and motivations internationally 
The funding dynamics and motivations of human embryonic stem cell research 
vary greatly internationally depending on the level of political opposition, the 
funder and also the cultural status of the embryo. A variety of funders have filled 
the space left by restrictions in the European Union and federal funding in the 
United States.1  
hESCR attracts funders with varying levels of motivation and accountability.1 
Funding sources include national or state public funding agencies, corporations, 
fundraising dependent non-profit organizations and independent 
philanthropists.1 The potential of financial gain, clinical promise and patenting 
motivate corporation funding in contrast to fundraising dependent non-profits 
whose research goals are to benefit their patient community. In Europe, 
philanthropists are becoming more significant with the private sector playing an 
increasing role in the provision of public goods due to the current economic 
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climate.1 However scientific norms such as peer-review do not apply to this 
group of funders as their motivation is usually personal.44  
From 2001 to 2009 there were many restrictions placed on the NIH due to the 
Bush Administration. During this period, non-profit organisations were created 
to specifically endorse hESCR, running independent laboratories with non-
federal funds.1 However despite educating patients and donors regarding the 
disease and research progress, these types of fundraising dependent non-
profits have struggled to manage the unrealistic expectations of their donors 
and disease communities.1 
Despite President Obama removing the restriction against federal funding of 
stem cell research in 2009, the Dickey-Wicker Amendment “remained an 
obstacle for federally funded researchers seeking to create their own stem cell 
lines.”1 The Amendment is the name of an appropriation bill rider attached to a 
bill passed by United States Congress in 1995 which prohibits the Department 
of Health and Human Services (HHS) from using appropriated funds for the 
creation of human embryos for research purposes or for research in which 
human embryos are destroyed.45 As highlighted by the Sherley v Sebellius case 
in 2010, Judge Royce C. Lamberth granted an injunction against federally 
funded hESCR on the grounds that the guidelines for such research "clearly 
violate" the Dickey-Wicker Amendment.46 This injunction was lifted in 2011 by 
the U.S. Court of Appeals for the District of Columbia Circuit with the appeals 
panel stating how the Amendment was "ambiguous" and that the National 
Institutes of Health had "reasonably concluded" that although federal funds 
could not be used to directly destroy an embryo, the amendment does not 
prohibit funding a research project using embryonic stem cells.47  
As previously published, the international hESCR policy environment is a 
“patchwork of patchworks”48 thus impacting funding priorities and the research 
conducted.49 Research in federated countries like the United States may be 
governed by an overlapping web of national and state laws, resulting in a 
mosaic of permissions and restrictions.48 Similarly, in the European Union a 
diverse legislative environment characterizes its member states. The liberal 
legislation regarding research on human embryos may be related to the barely 
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contended status of abortions in Sweden, differing sharply from Ireland and the 
US.50  
Public funders, as the most accountable, are tied to the policies of their political 
masters with strict financial and fiduciary obligations to tax payers and 
grantees.1 This manifests through formal processes of peer review and financial 
reporting. While subject to external political forces, these agencies are the least 
nimble in responding to changing research environments. Corporations by 
contrast are primarily driven by clinical promise and profit motives, and 
therefore may rapidly enter and exit research fields.1 While fundraising 
dependent non-profits and especially philanthropists are essential forms of 
funding in the early stages of research advancement, they are unreliable for the 
long timeframes necessary to advance cell therapies. Such funding sources 
may enter the field based on high expectations but may exit just as rapidly 
based on disappointing rates of progress. Because clinical trials have been slow 
to materialise with no approved therapies as yet and since the entry of public 
funders, fundraising dependent non-profits are re-evaluating their role and 
scaling back. 
2.5 Conclusion 
Regardless of differing opinions amongst scientists when it comes to hESCR, 
they are bound by their particular countries law and regulatory body to perform 
research in an ethical and lawful way. What is frustrating however is avoiding 
drafting a bill altogether surrounding this particular type of research which has 
clearly happened in Ireland until last year despite recommendations by the 
CAHR eleven years ago and Irish Council for Bioethics. Our only guidelines 
come from the Irish Medical Council which is not satisfactory to date and 
despite a proposed Bill, there is still no law or established regulatory body that 
guide and protect researchers. Our Government has been slow to address this 
issue ultimately in truth due to the 8th Amendment and the status our 
Constitution gives to the unborn. This is in stark contrast to countries like the UK 
and Sweden where there are defined laws and regulatory bodies and religion 
does not influence public policy debate.  
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Despite the various international discussions that are currently happening, the 
Irish surrogacy case MR and DR v An t-Ard-Chláraitheoir [2014] IESC 60 
highlighted how Irish law has failed to keep up with scientific progress regarding 
AHR.  In Ireland the embryo in vitro does not have constitutional protection due 
to a failure in our legislature to regulate AHR. This fact was highlighted by the 
Supreme Court in the case Roche vs Roche [2009] IESC 82.  Not only is the 
moral value of the embryo undermined but also along with the absence of an 
open and transparent embryonic research policy, any positive discussions 
regarding assisted human reproduction including research involving surplus IVF 
embryos is extremely limited. 
The Oireachtas need to do its legislative duty and provide a proper framework 
to regulate assisted human reproduction and therefore set limits on hESCR 
including germline gene therapy and mitochondrial DNA replacement therapy in 
Ireland thus protecting both the scientists, future children and society as a 
whole. 
Regarding the MR and DR v An t-Ard-Chláraitheoir [2014] IESC 60 case, the 
late Mr Justice Adrian Hardiman criticised politician’s legislative apathy as a 
situation where “road traffic law had failed to reflect the advent of the motor car”. 
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Chapter 3: The Law and Ethics of 
Engineering the Embryo  
3.1 Introduction 
Significant advances in gene editing therapy occurred last year which opened 
the flood gates to a series of questions from an ethical and legal perspective. 
These milestones in genetics have highlighted the lack of debate that has 
occurred in the scientific arena to date regarding developing a proper 
international regulatory framework for researchers to abide by.  
Even theatre and drama has encouraged discussions with the playwright 
Stacey Gregg debating the developments in a lecture entitled “In Genethics, 
Genomics and Geena Davies” as part of the Theatre of Change Symposium 
that occurred in the Abbey last month. A future run by “mutant lesbian social 
warriors” is suggested as a possibility due to the substantiation of fertility, 
germline engineering and gene selection resulting in obsolete sperm and thus 
men.1  
Undoubtedly the biggest milestone to occur was in April 2015 when researchers 
in China announced that they had used clustered regularly interspaced short 
palindromic repeat (CRISPR), the genome-editing technique to alter the 
genomes of nonviable human embryos.2 The work, led by Junjiu Huang, a 
gene-function researcher at Sun Yat-sen University in Guangzhou, involved 
attempts to modify the beta-globin gene, a gene that if mutated results in the 
blood disorders β-thalassaemia and sickle cell anaemia. Reactions to this 
ground breaking news were mixed amongst the scientific community, propelling 
the human gene-editing debate onto an international platform. 
An example of when a disease has a protective function is in fact sickle cell 
disease which if scientists were to have removed the gene that encodes for this 
disease thousands of years ago, humankind may have been wiped out by 
malaria.3 As a result there are ethical issues surrounding this type of therapy in 
particular the potential impact that germline gene transfer would have on future 
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generations but also the potential use of gene therapies for non-medical 
purposes such as genetic enhancement or as the media have coined the 
‘designer baby’.4   
Another milestone for gene therapy that occurred in 2015 was mitochondrial 
DNA replacement therapy or the three parent embryo which was approved by 
the House of Commons in the UK in February 2015. Shortly afterwards the 
House of Lords supported the legislation, making the UK the first state in the 
world to embrace the new technique. The technique is allowed under tight 
regulation. Researchers who wish to offer the service to couples still must apply 
for and receive a license from the country’s Human Fertilisation and 
Embryology Authority (HFEA).5 
The important ethical and societal questions that were raised have resulted in a 
flurry of scientific and policy meetings and statements. The 2015 annual 
conference of the Progress Educational Trust (PET) focused on the advent of 
new methods of making enduring changes to the human embryo.6 The themes 
of this conference were further developed at PET's follow-up event on the 20th 
January this year CRISPR/Cas9: Should We Be Using It to Experiment on 
Human Embryos? Governments and regulators have debated especially over 
the past year whether in fact to draw the line on gene editing in human embryos 
entirely.  
As recent as May, a group of scientists met at a closed door meeting at Harvard 
Medical School to privately discuss a project to create a synthetic human 
genome spurring both intrigue and concern because if successful, the synthetic 
genome could be used to create human beings without biological parents. The 
project will be a follow up to the original Human Genome Project contrasting in 
that instead of reading the DNA sequence of 3 billion chemical units, the human 
genome would be written, synthesising the units from chemicals.7  
 
While there is no doubt that gene therapy is an exciting novel technique that 
could potentially eradicate many genetic disorders in the future, there is no 
precedent. Around 7.9 million infants are born with birth defects annually with 
the majority of these attributable to a genetic defect.8 Approximately 3.2 million 
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of these will have a chronic disability, many with conditions that will be passed 
on to their own children.8 The novel therapy is fraught with many ethical and 
legal issues highlighting the need for the establishment of policy frameworks to 
ensure the technique is utilised in a streamlined, concordant manner. With the 
advances in mitochondrial DNA replacement therapy and validation by the 
HFEA, the slippery slope argument begins with a series of potential further 
events occurring as a result such as the potential to correct genetic mutations in 
not only the mitochondria but nuclear DNA pushing the ethical and legal 
boundaries. 
3.2 Gene therapy defined 
Germline (oocyte, sperm, zygote, and embryo) gene therapy targets the 
reproductive cells, transferring DNA into either sperm cells or oocytes. Any 
intervention made to the DNA at this point will affect future generations 
essentially allowing humans to direct their own evolution.2 This is in contrast to 
somatic gene therapy where the DNA of non-reproductive cells such a blood 
cells or bone marrow are targeted. In somatic gene transfer the recipient's 
genome is changed, but the change is not passed on to the next generation. 
More specifically germline gene therapy involves either insertion of genes into 
an early embryo in vitro or insertion of genes into the germ cells of the patient 
which will have no effect on the patient but rather any future offspring.4  
Gene transfer in general involves using a vector such as a virus to deliver the 
new gene to the appropriate target cells. The technique is not yet available 
outside clinical trials involving monogenic disorders, cancer, infectious diseases 
and vascular disease. The NIH will not fund any use of gene-editing 
technologies in human embryos.4  
The CRISPR/Cas9 system is a prokaryotic immune system that targets and 
cuts out foreign DNA in bacteria.2 The enzyme Cas9 locates its target using a 
single guide RNA that was re-engineered in 2012 to target any DNA sequence.9 
It has been adopted for gene editing because it can be designed to recognize 
and cut specific locations in the genome. Genome editing using CRISPR-Cas9 
systems in human cell cultures was first described in 2014.10  
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It is easier and quicker compared to the other two gene editing techniques that 
are currently being used; zinc finger nuclease (ZFNs) and transcription 
activator-like effector nucleases (TALENS) because these two technologies use 
proteins which take time to construct whereas CRISPR use the less time 
consuming RNAs. CRISPR technology is also better at editing more genes at 
one given time. Although CRISPR/Cas9 has been a major step forward in the 
accuracy of genome editing, it still frequently leads to modifications at sites in 
the genome other than that intended which is in contrast to TALENs.11 This 
potential “off target” edit is a major cause for concern regarding potential future 
applications in humans. A group at the Broad Institute of MIT and Harvard have 
recently improved the technique to significantly reduce off-target cleavage while 
maintaining robust on-target activity.12 
3.3 Clinical trials using gene editing techniques  
This summer there has been a flurry of activity worldwide to authorise clinical 
trials using gene editing technology. Yet again it is the Chinese that are leading 
the way in CRISPR clinical trials with a team at Sichuan University’s West 
China Hospital in Chengdu receiving ethical approval from the hospital's review 
board on 6th July for a Phase I Clinical trial. The group are now planning to start 
testing the CRISPR-Cas9 technology in August in ten patients with non-small 
cell lung cancer, starting with one patient and assessing side effect profile.  
Chengdu MedGenCell, a biotechnology company and a collaborator on the trial, 
will validate the cells to ensure that the correct genes are knocked out before 
the cells are reintroduced into the patients.13  
In June 2016, the Recombinant DNA Research Advisory Committee (RAC) at 
the US National Institutes of Health (NIH) approved a clinical trial proposal to 
use CRISPR–Cas9 to engineer T-cells in cancer patients who are taking 
immunotherapy drugs specifically the anti-PD1 monoclonal antibodies.14 The 
RAC panel has traditionally in the past vetted the safety and ethics of gene 
therapy trials funded by the U.S. government. This two year Phase I trial will 
recruit eighteen patients with melanoma, myeloma and sarcoma who have 
relapsed on treatment performing three CRISPR edits in their genome and 
assessing its safety profile. The Parker Institute at the University of 
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Pennsylvania will manufacture the edited cells, and will recruit and treat patients 
alongside the University of California, San Francisco and the MD Anderson 
Cancer Centre in Houston. Interestingly it will be funded by a US$250-million 
immunotherapy foundation formed in April by former Facebook president Sean 
Parker as opposed to federal funds with no budget as of yet. The university also 
has a financial interest in the trial, the trials scientific advisor immunologist Carl 
June already owns patents on using engineered T-cells to treat cancer and also 
advises companies developing these treatments. The group must now seek 
approval from their own institutions’ ethics boards and the U.S. Food and Drug 
Administration and if approved could start their clinical trial by the end of this 
year.13  
June was the principal investigator of a clinical trial published in the NEJM using 
the other gene editing technology ZFNs. An open-label, nonrandomized, 
uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells in 
twelve patients with HIV the gene that encodes a protein on T cells that the 
virus targets was removed. The primary outcome was safety and the technique 
is now being used in clinical trials.15 
In June 2016, researchers at Great Ormond Street Hospital for Children in 
London have begun a safety study with 10 children using the gene editing 
technique TALENS.14 This has happened after a baby girl with acute 
lymphoblastic leukaemia was successfully treated with the gene editing 
technique in November 2015.16  
The Biotech start-up  company Editas which was set up in 2013 in Cambridge, 
Massachusetts by CRISPR pioneers announced its plans at the EmTech 
conference in November 2015 to use CRISPR in a clinical trial for a rare form of 
blindness Leber congenital amaurosis as soon as 2017. As of July 2016, the 
RAC have not yet been approached about reviewing the trial.14  
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3.4 Mitochondrial DNA Replacement Therapy 
Mitochondrial DNA replacement therapy is an in vitro fertilisation technique and 
considered a form of gene therapy that uses the mitochondrial DNA from a 
healthy donor egg.5 It involves removing the nucleus of one egg (the mother) 
and inserting it into the cytoplasm of another egg (the donor) which has had its 
nucleus removed, but still contains normal mitochondrial DNA. This hybrid egg 
is then fertilised with a sperm ensuring that the egg will contain a nucleus with 
genetic material from only the two parents. The DNA contained in the donated 
mitochondria comprises less than 1% of the total genetic contribution and does 
not affect the inherited DNA in the nucleus which shapes the individual 
character and traits of recipients.5 
An international team led by researchers at the Salk Institute for Biological 
Studies in La Jolla, California, published results in Cell in April 2015 of a method 
developed to selectively remove mutated mitochondrial DNA from the murine 
germline and single-celled mouse embryos.17 The scientists hope to offer the 
technique as an alternative to mitochondrial DNA replacement therapy 
removing the donor from the equation. 
3.5 The Ethical Debate 
Ethical questions surrounding this controversial type of therapy include: 
1) Do the benefits outweigh the risks? Is it affordable and necessary? 
2) Does it affect human rights? Are we doing this for the benefit of children 
or prospective parents? 
3) Who decides which traits are normal and which constitute a disability or a 
disorder? 
4) Is it therapy or enhancement? 
5) What will be the social consequences? Will it reduce the care of 
vulnerable people? Will the techniques lead to a less caring society, less 
accepting of people who are “different”? 
6) Is there a difference between treating somebody before or after birth? 
Can treating somebody who does not exist be termed a therapy at all? 
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3.5.1 Arguments against germline gene therapy 
The effects of gene therapy are too unpredictable and could affect the 
development of a fetus in unexpected ways or have long-term side effects that 
are not yet known. Even if the therapy successfully cures the disease, other 
mutations can potentially be introduced which will also be passed on to the next 
generation. A genetic mutation may have a protective role that we currently are 
not aware of.18  
Specific worries include:  
a) The vector may introduce DNA into alternative cells other than the target 
cells. 
b) The target cells may transfect another cell. 
c) The vector may trigger the immune system resulting in an inflammatory 
response and toxicity. 
d) Genes may not be inserted into the accurate location in the nucleus. 
e) Integration with other DNA already in the nucleus may not be 
successful18  
Compared with IVF and screening for healthy embryos pre implantation, the 
technique introduces additional risks to the embryo and will never be effective 
enough to rule out the need for post-fertilisation screening of embryos. There is 
currently a paucity of compelling medical applications justifying the use of 
CRISPR/Cas9 in embryos. The whole process is unnecessary and irrelevant as 
pre implantation genetic testing which is cheaper and technically easier is 
currently available.19  
Concerns involve issues ranging from: a) the autonomy of future individuals, b) 
the application of these technologies, c) "enhancement" rather than treating 
disease and d) the boundaries of reproductive liberty.  
Unlike somatic gene therapy, the person being affected by germline gene 
transfer, do not yet exist. Thus, the potential beneficiaries are not in a position 
to consent to or refuse such a procedure.4 Rather than treating an existing 
person with a disease, the technique ensures that a person is not brought into 
existence at all, inviting discrimination and implying that some people are not 
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worthy of a life based on their genetic makeup. Beginning to classify the worth 
of others is akin to eugenics.20 Germline engineering also brings us closer to 
designer babies perpetuating inequality and violating basic principles of self-
determination.3  
3.5.2 Arguments in favour of germline gene therapy 
Germline gene therapy enables the correction of disease-causing mutations 
that are certain to be passed on from generation to generation, sparing future 
generations from suffering from the disease. It enables the generation being 
treated to lead a healthy life. Conditions like Huntington's disease could become 
diseases of the past using gene therapy, in the same way that global 
vaccination programmes have eradicated diseases like polio.19  
While pre-implantation genetic diagnosis of IVF embryos is both cheaper and 
simpler, if both parents carry the genetic disorder, every embryo they conceive 
will have the genetic disease.3  
No unborn child, whether conceived naturally or artificially through IVF and 
germline gene therapy, is able to choose their genetics and whether they are 
born with or without a particular condition.19 Parents inevitably make decisions 
for future generations that children cannot consent to, the moral imperative is to 
make the right decisions. It is a fallacy to say that the germline is sacred and 
genome editing should not be pursued because it affects future generations as 
this is also true for all assisted conception techniques and, indeed, all 
reproduction.20   
Human reproduction albeit a normal physiological process can be considered 
dangerous perhaps even more so than genome editing. Given that some people 
affected by genetic conditions, like mitochondrial disease, will continue to 
reproduce without treatment, the decision becomes a choice between a form of 
reproduction with risk and the other with the possibility of risk that might never 
happen.20  
Clinical use in the UK is currently not possible without further legislative action 
and it is a criminal offence to carry out research without a licence thus abuse of 
this type of therapy is minimised. The Gene Therapy Advisory Committee 
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(GTAC) regulates the use of gene therapy in the UK. This regulation prevents 
gene therapy being used to select characteristics for non-medical purposes 
such as enhancement or to produce a “designer baby”. Potentially harmful 
consequences associated with emerging genetic research are avoided 
altogether by the US National Human Genome Research Institute because their 
aim is to consider all of the ethical issues associated with the novel technique.19  
In most societies and cultures we have the freedom to pick the best genes for 
our children in the type of “mate” we choose. This is a matter of basic 
reproductive freedom. Why should we have less freedom to give our children 
the best genes we can through genetic enhancement? 
Even cultures where arranged and consanguineous marriages are 
commonplace, an acknowledgement of the “burden” associated with genetic 
disorders has occurred in recent times. In Orthodox Jewish circles, the 
organization Dor Yeshorim carries out an anonymous screening program so 
that couples with Tay–Sachs or another genetic disorder can avoid conception. 
Some Muslim societies are performing genetic testing to outrule genetic 
disorders prior to the arranged marriage to reduce the transmission of disorders 
associated with consanguineous marriages.  
The Government of Kuwait issued a declaration in 2009 by the Assistant 
Undersecretary of Kuwaiti Ministry of Health for Medical Services, Dr. Yousuf 
Al-Nesf, stating, “The new marriage law providing for pre-marriage checkup will 
be in force on Sunday, August 2, 2009.” … "The aim of the legislation is to 
ensure a healthy and happy family and eradicate the hereditary and 
communicable diseases in Kuwait".21 
If the tests prove that the would-be marriage is unsafe due to the illness of one 
or both of the partners, the marriage contract is cancelled. "A marriage officer is 
authorised to solemnise a marriage only after receiving a certificate that verifies 
that the couple conducted a check-up and were physically fit”.21 
Finally Transhumanists highlight that many people are already trying to improve 
themselves through diet, exercise, education and cosmetic surgery. Exercising 
to improve strength and overall health is considered to be worthwhile so is 
pursuing an education to increase their mental calibre. Surely then it would be 
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worthwhile to accomplish these through gene therapy thus improving genetic 
makeup.18 
3.6 Regulation 
 
Human germline gene modification is largely forbidden by law or guidelines 
even in countries that are permissive to human embryonic stem cell research.22 
Bioethicists at Hokkaido University in Japan analysed relevant legislation and 
guidelines in 39 countries and found that 29 have regulations that could be 
interpreted as restricting genome editing for clinical use.23 However, the 'bans' 
in several of these countries, including Ireland are not legally binding. The 
regulatory landscape suggests that human germline gene modification is not 
entirely prohibited worldwide.  
 
The UK has a robust regulatory system banning genome editing for clinical use. 
The Human Fertilisation and Embryology Act 1990 prohibit the use in treatment 
of oocytes, sperm cells or embryos which have had their nuclear DNA modified. 
The Human Fertilisation and Embryology Authority (HFEA) regulatory body may 
permit human genome editing for research insisting that scientists apply for a 
licence. Clinical use is not possible without further legislative action and use 
without a licence would be a criminal offence.  
In the US, there are multiple existing legislative and regulatory prohibitions. The 
Dickey-Wicker amendment prohibits the use of appropriated funds for the 
creation of human embryos for research purposes or for research in which 
human embryos are destroyed (H.R. 2880, Sec. 128). Moreover, the NIH 
Guidelines state that the Recombinant DNA Advisory Committee, “…will not at 
present entertain proposals for germ line alteration”. It is also important to note 
the role of the FDA in this arena, which applies not only to federally funded 
research, but to any research in the U.S. Their regulations apply to all clinical 
gene transfer research, while the NIH governs gene transfer research that is 
supported with NIH funds. The Public Health Service Act and the Federal Food, 
Drug, and Cosmetic Act give the FDA the authority to regulate cell and gene 
therapy.24 
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Even though researchers cannot use federal money for experiments that alter 
the genomes of human embryos, they can use other sources of funding 
because the technique of gene editing is not banned.24 
Specifically Ireland, Japan, China and India have unenforceable guidelines that 
restrict genome editing of human embryos. In Ireland there is no national policy 
on human embryonic stem cell research despite the Supreme Court ruling of 
the case Roche vs Roche [2009] IESC 82 that the life of the unborn under 
Article 40.3.3 of the Irish Constitution does not include the embryo in vitro. 
Under current Irish law there is also no legal constraint on the importation and 
use of human embryonic stem cells in research. Protection against embryonic 
stem-cell research in this State has come from the guidelines of the Irish 
Medical Council, which hold that such work is unethical. Given that creating 
embryos specifically for research is prohibited, germline gene modification for 
reproduction is also interpreted as banned. In the absence of any legislative 
regulation of assisted human reproduction, mitochondrial donation and gene 
therapy would also conflict with the Irish Medical Council guidelines.25 
Therefore the same regulatory issue that arises from research involving 
embryonic stem-cell research in Ireland applies also to germline gene therapy.  
3.7 Discussion 
 
The US National Institutes of Health reaffirmed its ban on funding gene-editing 
research in human embryos in response to rapidly increasing research using 
genome-editing techniques, such as CRISPR.26 
In contrast five UK research organizations, including the Wellcome Trust and 
the Medical Research Council issued a statement in September 2015 urging the 
continued use of CRISPR/Cas9 in research with human embryos when ethically 
justifiable and legal. A week later, the Hinxton Group, a network of stem-cell 
researchers, bioethicists and policy experts concluded that research involving 
genome editing in human embryos has "tremendous value to basic research".26 
Scientists from the Francis Crick Institute in London submitted an application in 
October 2015 to edit the genomes of human embryos using technology based 
on the CRISPR/Cas9 system to identify genetic mutations that affect early 
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development as possible causes for miscarriages and infertility. This request for 
a licence is the world’s first approval of such research by a national regulatory 
body, the HFEA who authorised gene editing in human embryos for research 
purposes using 120 surplus IVF embryos donated by parents in February 2016. 
Following these events, the Britain's Royal Society and the Chinese Academy of 
Sciences announced that they would collaborate with the US National Academy 
of Sciences and the Medicine to host a summit in December 2015 on germline 
editing. The aims of which were to develop a framework to guide national 
legislation and to produce recommendations for responsible use of the 
technique in 2016.  
Attendees at the international summit included a group led by Harvard 
geneticist George Church who has used the CRISPR/Cas9 gene-editing 
technology to inactivate sixty two porcine endogenous retroviruses (PERVs) in 
pig embryos to make the animals’ organs suitable for transplanting into humans. 
These viruses are embedded in all pigs’ genomes and cannot be treated or 
neutralised and as a result could cause disease in immunocompromised human 
transplant recipients.27  
Opinions varied at the summit discussing the main question of whether gene 
editing should be used to alter human inheritance. Dr. George Daley of Boston 
Children’s Hospital and Harvard believes editing human embryos “can be safely 
done if we chose to do it.”3 
CRISPR pioneer Jennifer Doudna of the University of California, Berkeley and 
sixteen others wrote for Science in March 2015 urging scientists to “strongly 
discourage . . . attempts at germline genome modification for clinical application 
in humans,” but left the door open to such research if it doesn’t lead to a 
pregnancy.3 
Scientists, clinicians, patients and ethicists spent three days discussing the pros 
and cons of genome editing, which led to an agreed statement from the 
Organising Committee about how to proceed.11 They agreed that gene therapy 
should be used in a research domain to improve the technique and better 
understand the risks involved but any of the embryos or germlines edited should 
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not continue into a pregnancy. The committee felt that germline cell editing to 
avoid severe inherited diseases or enhance human capabilities would currently 
be irresponsible and that the ethical and societal issues associated with the 
technique need to be explored in much greater detail. 
Finally, the committee recommended setting up an international forum to lead 
on further work in this area: “The international community should strive to 
establish norms concerning acceptable uses of human germline editing and to 
harmonize regulations, in order to discourage unacceptable activities while 
advancing human health and welfare.”11 
It is worth considering who will benefit most from gene editing? The Committee 
on Human Gene Editing held a summit for scientists, lawyers and ethicist in 
Paris in May 2016 as part of the US National Academics of Sciences, 
Engineering and Medicine discussing this point with the following outcome: it is 
women and in particular disabled people who need to be involved in any 
policies that will arise in the future. Interestingly women will benefit from gene 
editing in two ways: they tend to be caregivers for disabled people and also 
therapies to improve fertility will be targeted at females. The international 
committee are currently drafting a set of recommendations reviewing its 
potential wider implications with a report due later this year. 
Finally a symposium specifically for genome editing and therapy will be held in 
Hannover to “help identify the scientific, clinical and regulatory hurdles that 
remain to be overcome” with the 2nd Annual Genome Editing congress in 
London both to be held in November 2016. 
3.8 Conclusion 
Researchers who work on CRISPR have a duty to consider not just the science 
but also how it will be received by the public. If a country positively considers 
corrective genome therapy, preventive measures against abuse of the therapy 
would be required with the formation of a global consensus. Thinking about 
germline gene therapy involves ethical, social, and evolutionary considerations 
for all of humankind.23  
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Chapter 4: Alternative Sources and 
Methods of Creating Stem Cells 
 
4.1 Introduction 
 
Of course there are indeed other sources of stem cells that are currently being 
used regularly in clinical practice called “tissues stem cells” or adult stem cells. 
Although adult stem cells are not pluripotent in contrast to embryonic stem cells 
and are therefore limited to differentiate into their cells of origin, they play an 
important role in regenerative medicine. Isolating stem cells in adult cells is a 
difficult technique as these cells are not readily in abundance in contrast to 
embryonic stem cells which are easier to culture. Research into circumventing 
and indeed manipulating their pathway has become the focus of intense 
research especially in the past decade. The different types of adult stem cells 
and alternative techniques such as somatic cell nuclear transfer and 
reprogramming are discussed in this chapter along with the similarities 
embryonic stem cells have to cancer stem cells. The ethical issues surrounding 
iPSCs are compared and contrasted to hESCs highlighting the need for 
appropriate regulation. 
 
Tissue stem cells include the following: 
 
a) Peripheral blood stem cells which have been in use since the 1970s in 
patients with haematological malignancies to perform a bone marrow 
transplant. Haematopoietic stem cells were the first stem cells discovered in 
the 1960s and can be found in peripheral blood cells, bone marrow and 
umbilical cord blood.1  
b) Skin tissue engineering has used for burns patients since 1981 using 
cultured epidermal autografts and an artificial dermis.2  
c) Umbilical cord blood contains haematopoietic stem cells and is an 
alternative source to bone marrow with over 20,000 patients receiving an 
umbilical cord transplant in the past 20 years.3 These specialised blood cells 
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are currently being used to treat paediatric haematological cancers as well 
as genetic blood diseases like Fanconi anaemia.3 It is technically more 
challenging to use in adults as they require a greater volume of cord blood 
compared to bone marrow. However there does though appear to be less of 
an immune response compared with bone marrow transplant which makes 
them a more attractive option. Umbilical cord blood contains fetal stem cells 
which traditionally have been considered too immature or naïve compared to 
adult cells to mount an immune response at all. Surprisingly research 
published last year dispelled this theory and demonstrated that cord blood T 
cells mediated an enhanced antitumor effects compared with adult 
peripheral blood T cells in a xenogeneic mouse model with B-cell 
lymphoma.4  With over 130 public cord blood banks in 35 countries, this is a 
popular source of stem cells to treat haematological diseases.3 There is a 
debate as to whether parents should use private cord blood banks for 
potential use in the future in case their own child may need it, however if the 
child were to develop leukaemia, their own cord blood cells could not be 
used nor would one sample be sufficient so donation to a public blood bank 
would mean that the cells would have more of a chance of being utilised and 
thus would serve society better as a whole.5  
d) Mesenchymal stem cells are multipotent cells found in bone marrow and can 
potentially differentiate into three completely different types of cells found in 
skeletal tissue; osteocytes, adipocytes and chondrocytes.6 They are not 
currently being used in treatment but there are early clinical trials looking at 
their use in bone and cartilage repair.7 Promisingly a recent small-scale 
phase II trial demonstrated that during coronary artery bypass surgery 
mesenchymal stem cells that are injected into the scar tissue in 11 patients 
with ischaemic cardiomyopathy have the potential for in situ myocardial 
regeneration. There was a 40% reduction in the size of the myocardial scar 
tissue 12 months after tteatment.8  
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4.2 Somatic Cell Nuclear Transfer 
Therapeutic cloning creates an embryonic stem cell line that is available to be 
used in tissue culture, research and potentially treatment. It does this by a 
process called somatic cell nuclear transfer (SCNT) which transfers a somatic 
adult cell’s nucleus into an egg that has had the nucleus removed, an 
enucleated oocyte. Figure 4.1 illustrates this process. The nuclear transfer 
leads to genome reprogramming. This embryo “hybrid” is a way of preparing 
pluripotent cells for research purposes only i.e. not for reproductive cloning and 
is an alternative approach to ESCR. This was the technique used to create 
Dolly the sheep in 1997.19 However, this method is technology intensive and the 
reprogramming yield is very low. Moreover, this approach also encounters 
similar ethical problems that are associated with hESCR such as the generation 
of many human ovarian cells and destruction of an embryo.9 An abundance of 
eggs are also required to carry out these experiments, in fact 277 nuclear 
transfers were performed to create one viable embryo in Dolly’s case.19 Since 
then the technique of course has been optimised with not near as many nuclear 
transfers required now but it still requires many eggs. Given that this technique 
relies on egg donation, exploitation of women could happen especially in 
developing countries similar to the surrogacy debate.  
64 
 
 
Figure 4.1:- Schematic illustration of somatic cell nuclear transfer.
19
  
 
4.3 Induced Pluripotent Stem Cells 
 
Since the discovery of iPSCs in 2006 by Yamanaka,10 eight years after the first 
hESCs were successfully cultured in vitro, an alternative method to stem cell 
discovery which did not involve destruction of an embryo was now available as 
an alternative method potentially bypassing all the ethical issues associated 
with hESCR. The novel technique was awarded a Nobel Prize in Physiology or 
Medicine in 2012 as it revolutionised our understanding of cell biology.11 This 
ground breaking technique along with the already established 
transdifferentiation technique could indeed replace hESCR entirely. However 
cell reprogramming and regenerative medicine pose their own challenges and 
ethical debate thus altering the discussions. 
 
IPSCs involve reprogramming of fully differentiated somatic cells such as adult 
skin cells into pluripotent stem cells that are almost identical to ESCs by the 
ectopic expression of four genes, Oct4 , Sox2 , Klf4 , and cMyc. Figure 4.2 
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demonstrates this process. Transdifferentiation on the other hand is a technique 
that was initially discovered in the 1980s and uses transcription factors to 
convert a given cell type directly into another specialized cell type, bypassing 
the pluripotent state entirely.11 An example of this technique is converting 
fibroblasts directly into muscle cells. A previous limitation of this procedure is 
that only cells from the same “family” or the three main germ layers (mesoderm, 
ectoderm, endoderm) could be successfully converted such as white cells; 
lymphocytes into macrophages. This limitation was overcome in 2010 with a 
renewed enthusiasm and research into the technique probably related to 
Yamanaka’s discovery. The group in Stanford showed that fibroblasts could be 
converted into functional neurons by introducing three neuronal transcription 
factors transitioning the germ layers of mesoderm to ectoderm.12  
Since then more successful germ layer transitions with reprogramming have 
occurred.13   
 
 
Figure 4.2:- Schematic illustration of a) reprogramming somatic cells into pluripotent stem cells 
by expression of the four genes Oct4 , Sox2 , Klf4 , and cMyc, b) the potential applications of 
the iPSCs for patient specific cell therapy, drug screening and human disease models and c) 
the gene delivery methods.
12  
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4.4 Technical issues and patient safety 
 
The issues of immunogenicity and cell rejection that occur in organ 
transplantation should be avoided altogether because it is the patient’s own 
cells that are reprogrammed into a pluripotent cell. However this has not 
appeared to be the case with studies revealing the abnormal epigenetics, 
genomic stability and immunogenicity of iPSCs thus raising valid safety 
concerns over iPSC-based therapy.14 There is little understanding as to why 
some iPSCs are rejected and others were not.  Last year a group from the 
University of California published a study addressing the key questions in 
regenerative medicine.15 The group used a humanized mouse model 
reconstituted with a functional human immune system and demonstrated that 
autologous human iPSC-derived retinal pigment epithelial (RPE) cells are 
immune tolerated even in non-ocular locations. This was in contrast to 
autologous human iPSC-derived smooth muscle cells (SMCs) which appeared 
to be highly immunogenic. This differential immunogenicity is in part due to the 
abnormal expression of immunogenic antigens in human iPSC-derived SMCs 
that are not expressed in human iPSC-derived RPEs. These findings support 
the possibility of developing human iPSC-derived RPEs for treating macular 
degeneration offering much hope to patients with macular degeneration.15  
 
Reprogrammed cells must be free of viral vectors inserted into the DNA that can 
potentially cause mutations and thus cancer. iPSCs have overcome this 
stumbling block by the utilisation of small molecules and modified mRNA. Most 
current protocols now use retro- or lentiviral vectors to introduce combinations 
of transcription factors.16 This alternative approach is to induce cell fate 
conversions by transiently expressing microRNAs.16  
 
Genomic instability in iPSCs is an established undesired result of 
reprogramming. Human iPSCs have a high propensity for developing genomic 
abnormalities, which is likely due to the “uncoupling” of checkpoint activation 
and apoptosis.17  
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Many age-related diseases are associated with telomere shortening18 and 
interestingly Dolly the sheep, the first animal derived from adult cells19 had 
telomeres that were shorter than other sheep her age. Given that Dolly was 
cloned from adult tissues (via the somatic cell nuclear transfer technique) and 
suffered from diseases such as osteoarthritis, it is very well  a possibility that 
Dolly was biologically older that her age. Cells remember their age, an example 
of this is Dolly and thus iPSCs may also be affected by the age of cells they 
have originally come from. 
Researchers have subsequently studied whether cloning accelerates the aging 
process to clarify the situation. In July 2016 on the 20th anniversary of Dolly’s 
birth, a group published the first study to assess the long-term health outcomes 
of SCNT in large animals. Interestingly the group demonstrated that SCNT has 
no obvious detrimental long-term health effects in a cohort of 13 cloned sheep 
including four derived from the cell line that gave rise to Dolly.20  
These promising results could potentially be applied to the iPSC research 
arena. 
 
P53 is a tumour suppressor gene that is commonly mutated in cancer and a 
common reprogramming approach used to create iPSCs is where p53 is 
knocked down by an shRNA in other words its activity is effectively turned off. 
Interestingly there is a significantly lower incidence of cancer in patients with 
Huntington’s disease, most likely due to this tumour suppressor protein.21 p53 
activity normally inhibits reprogramming to the pluripotent state, hence p53 
knockdown increases efficiency of reprogramming.22  
The increased genomic instability seen during reprogramming of fibroblast cells 
of patients with Huntington’s disease is likely due to this p53 knockdown.23  
 
Moreover tailor-made cells specific to each patient is time consuming, inefficient 
and costly. Given that the cells are patient specific, standardisation will also be 
a challenge.24 What is more realistic is to develop a bank of cells with different 
immune properties so that compatible matches can be found for most patients. 
These cell banks could contain cells made from either hESCs or iPSCs.24  
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4.5 Clinical trials and regulations involving iPSCs 
 
Given the uncertainties with iPSC therapy in regenerative medicine such as 
cancer development and immunogenicity, clinical applicability has been 
hindered. In March 2016, an alternative radical treatment modality was 
published using endogenous stem cells to gain vision in human infants by 
isolating lens epithelial progenitor cells (LECs). Twelve paediatric patients with 
bilateral cataracts received the novel minimally invasive surgery to promote lens 
regeneration versus the control group of twenty five paediatric patients who 
underwent the current standard of care treatment of lens removal and 
replacement with an artificial lens.25 All eyes regained visual function in new 
treatment arm thus highlighting an alternative treatment modality for tissue 
regenerative medicine using endogenous stem cells.25 
 
To date, there has been no clinical trial involving human iPSCs.26 This is in 
comparison to the FDA approved clinical trials involving hESCs which have 
been approved since 2009 primarily focusing on ophthalmology related 
diseases such as macular dystrophy and degeneration. The main reasons 
being that the culturing technique is not considered “clinical grade” and 
therefore unsafe for patients. Current techniques involve genetic modification 
involving transcription factors and oncogenes that are seen in cancers, which 
can potentially result in mutations and the development of a tumour. IPSCs can 
as a result grow and differentiate indefinitely, a process that would need to be 
tailored and effectively switched off. Prior to use in humans, the cells must also 
be shown to differentiate fully into the required types of specialised cells in a 
reproducible manner to safely meet the current standards. 
 
Retinal epithelial cells are the focus of intense research because it is 
degeneration of the epithelium that results in the leading cause of blindness in 
people over 65 years age, macular degeneration. A group at the Neural Stem 
Cell Institute in Rensselaer, New York have successfully isolated, cultured and 
re introduced retinal pigment epithelial stem cells into mouse models preventing 
degeneration.26 The group is currently in pre-clinical trials with rats and hope to 
start human clinical trials in the two years.26 
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The research institute in Japan, Riken Centre for Developmental Biology 
successfully conducted a retinal transplant in 2014 using induced pluripotent 
stem cells on a patient suffering from age related macular degeneration.27  
The principal investigator was the ophthalmologist Takahashi who first 
discovered iPSCs with Yamanaka in 2006. In March 2015, a second trial was 
suspended after genetic mutations were identified in the patient’s cells. 
Interestingly research published in April 2016 by a group in South Korea 
demonstrated that the older a patient is, the more likely it is that iPSCs derived 
from them will carry genetic mutations that could affect the cells’ function.28  
Japans new regenerative medicine laws came into effect in November 2015 
whereby a regenerative medicine product can be approved for marketing if it is 
shown to be safe. Following approval and without a prior clinical trial, it would 
have up to seven years to prove efficacy. Takahashi’s group now are using 
partially matched donor cells as opposed to the patient’s own cells therefore 
speeding up the therapies development and in June 2016 it was announced 
that the retinal iPSC transplant study will resume in collaboration with Kyoto 
University where Yamanaka will supply the donor iPSCs. 
 
Encouragingly in June 2016, the NIH Regenerative Medicine Programme 
successfully cultured iPSCs from human umbilical cord blood cells that can now 
be used safely in clinical trials. These “clinical grade” stem cells can now be 
used in clinical trials involving humans after being developed under the 
regulations of good manufacturing practices (cGMP) guidelines that were 
enforced by the FDA.29 In contrast to “laboratory grade” stem cells, these cells 
have passed quality and safety regulations that now allow them to be used in 
patients. The European Medicines Agency and the World Health Organisation 
(WHO) also provide guidance to the GMP to ensure quality standards are met 
for optimal patient safety. 
 
“...providing access to clinical-grade stem cells removes a significant barrier in 
the development of cell-based therapies”29 
 
This is on the back the Biotechnology Company, Lonza publishing an open 
access paper in October 2015 providing a guide for a robust and reproducible 
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GMP-compliant manufacturing process for these clinical-grade iPSCs along 
with a bio bank of iPSCs to be made publically available.30 
 
The NIH Regenerative Medicine Programme also collaborates with the Stem 
Cell Translation Laboratory (SCTL) providing funding. The lab is administered 
by the NIH’s National Centre for Advancing Translational Sciences (NCATS). 
The aim of the SCTL is “to remove barriers that currently impede the 
therapeutic application of iPSCs” to ensure “highly reproducible and well-
defined procedures required to generate characterise and differentiate patient-
specific iPSCs in a safe fashion for pre-clinical and clinical use”.29 
 
4.6 Ethical issues surrounding iPSCs 
 
Despite President George Bush hailing iPSC research as a sign of “scientific 
advancement within ethical boundaries”, with subsequent U.S. progress in iPSC 
research under Bush’s policies, the technology is not without potentially serious 
ethical issues.30  
In simplistic terms, the technique that is involved in reprogramming skin cells 
into iPSCs is not difficult. Yamanaka’s original technique involved cloning four 
familiar genes into viral vectors and introducing these vectors into the skin 
cells.10 Therefore any scientist can be easily trained to carry out this method, 
the learning curve of optimal culturing techniques can be overcome. No 
application to a regulatory body is necessary to carry out these experiments 
which will be difficult to monitor by regulators.  
 
In contrast to hESCR, the source and method of creating iPSCs are not 
controversial but the potential applications could be. For example in the case of 
infertility, using skin cells of a man that could potentially be reprogrammed into 
an egg or sperm cell and the genomic instability associated with this. To date 
this has not yet been performed on human cells. The potential to create an 
iPSC-derived gamete from male cells in itself presents a new ethical dilemma 
as it could potentially alter the landscape of reproductive and fertility research in 
the future. Moreover cells that can be used to develop new life forms through 
advanced technology should be treated and respected the same regardless if 
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they are reprogrammed skin cells or embryonic stem cells. Should a special 
moral status be given to the skin cells normal function i.e. active potency or 
rather the iPSCs that are created from the skin cells? 
 
The issues surrounding hESCR in terms of clinical availability and accessibility 
to large numbers of patients is also present for iPSC treatment. The moral 
argument persists: who will have access to these new treatments in the future? 
To date public umbilical cord banking or publically funded IVF treatments are 
not available in Ireland. It seems difficult to identify any clear differences 
between hESC and iPSC-based therapies in this respect.  
Yamanaka believed in the development of government led regulations due to 
the ethical issues surrounding iPSCs. In 2008, Japan's science ministry sent all 
universities and research agencies a notification specifically forbidding “the 
implantation of embryos made with iPSCs into human or animal wombs, the 
production of an individual in any other way from iPSCs, the introduction of 
iPSCs into an embryo or fetus, and the production of germ cells from iPSCs”. 
Yamanaka says that society, not scientists, must quickly deal with the 
challenges that iPSCs present. “I am proud of this technology, but I feel a great 
responsibility”32 
 
4.7 Cancer, stemness and cancer stem cells; similarities to embryonic 
stem cells 
 
Epithelial plasticity is defined as the ability of cells to dynamically switch 
between different phenotypic cellular states.33 To become motile and invasive, 
embryonic epithelial cells undergo a process of mesenchymal conversion 
known as epithelial-to-mesenchymal transition (EMT).34 EMT is the transition 
from a sessile, epithelial cell to a motile cell with a mesenchymal phenotype.35 
EMT can also be seen in cancer cells as they leave the primary tumour, 
disseminate to distant organs and form metastases.34 In addition, through the 
reverse process (mesenchymal-to-epithelial transition), both normal and 
carcinoma cells revert to the epithelial phenotype to, respectively, differentiate 
into organs or form secondary tumours. The parallels in phenotypic plasticity in 
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normal morphogenesis and cancer highlight the importance of studying the 
embryo to understand tumour progression and to aid in the design of improved 
therapeutic strategies.34  
The term “cancer stemness” means the ability of cancer cells to self-renew and 
differentiate into tumour cell types.36 These two same properties of self-renewal 
and pluripotency are also exhibited by embryonic stem cells.37 As previously 
mentioned, cancer stem cells, CSCs are defined as tumour-initiating cells with a 
self-renewal capacity similar to that of normal stem cells.38  
While CSCs represent only a small proportion of the total cancer cell 
population,39 they are considered hypermalignant, tumorigenic and can give rise 
to the heterogeneous lineages of cancer cells that make up the bulk of the 
tumour.36 In addition, CSCs also possess the ability to mobilize to distant sites 
while retaining their stemness properties and thus regrow the tumour at these 
sites.39  
A mechanism of chemoresistance in cancer is the ability of the cancer cells to 
bypass regulated, programmed cell death mechanisms such as apoptosis 
resulting in a dysregulated growth pattern and de- differentiation from the 
original tissue of origin.  Figure 4.3 highlights the cancer stem cell concept. 
CSCs are thought to be particularly resistant to standard chemotherapeutic 
agents and are considered to be responsible for relapse after therapy. Because 
CSCs have the ability to become dysregulated and bypass normal cell death 
mechanisms thus potentiating their resistance to targeted therapies, they have 
become the intense focus of more effective therapeutic strategies.  
Overlapping characteristics are shared by ESCs and cancer cells have led 
investigators to examine the gene expression patterns that underlie these 
similarities.40 Activating a particular gene expression programme in normal adult 
cells resulted in iPSCs indistinguishable to ESCs10 which gives rise to the 
possibility of creating other types of stem cells, such as cancer stem cells using 
the same ESC-like gene expression panel. This was achieved in 2008 by Wong 
et al with human adult keratinocytes by reprogramming them into cancer stem 
cells through activation of the same ESC transcriptional programme used to 
create iPSCs, thus creating induced cancer stem cells or iCSCs. Therefore 
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even though the gene expression profiles of adult and embryonic stem cells 
differ, embryonic stem cells share transcriptional programmes with cancer stem 
cells.41 This is confirmed in mice models where mice derived from iPSCs 
frequently develop cancers thus posing a challenge for regenerative medicine.42 
 
Figure 4.3:- Schematic illustration of the cancer stem cells hypothesis. How cancer cells 
develop a chemo and radioresistance by cancer stem cells evading cytotoxic therapy.
41 
 
4.8 Conclusion 
Embryonic stem cells are the reference standard. Every new technology is 
compared to it and to date there is no other technique that can or arguably 
should replace it. Indeed the discovery of iPSCs was based on our 
understanding of hESC biology. Despite the wide categories of stem cells and 
sources, it is not yet clear which type of cells will be most useful for which types 
of treatments. 
More research is needed to establish how similar or indeed different iPSCs are 
to hESCs before we can answer the ethical questions posed. Research on all 
types of stem cells should continue so we can continue to question and 
understand the techniques involved in order to optimise efficacy and as a result 
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patient safety. These techniques should be used in tandem with each other and 
not yet considered a replacement technique.42  
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Chapter 5: Conclusion and Future 
Considerations 
 
5.1 Conclusion 
 
In 2016 there have been significant advances in hESCR technology with 
researchers pushing the boundaries creating ethical debate and questioning 
current legislations. CRISPR technology has been progressing at such a fast 
pace since the technology was successfully applied to non-viable human 
embryos in April 2015.1 Indeed it is now entering clinical trials in both the US 
and China without much debate in the public arena.2,3 The question of whether 
society as a whole is ready for it remains to be seen.  
 
However despite all of these novel developments, there is still a persistent legal 
vacuum in Ireland regarding hESCR with no specific legislation to date.4 This is 
in contrast with the rest of Europe where despite different viewpoints on the 
moral status of the embryo reflective in legislation, other European countries in 
particular UK, Germany, Spain and Sweden have well-defined and 
comprehensive regulatory frameworks.5 The human embryo in vitro does not 
have constitutional protection in Ireland, unlike Germany which protects the 
embryo under their Constitution, the moral value of the human embryo is 
undermined in Ireland.5,6 With no apparent support or funding from the 
Government to pursue this research, scientists are left to adopt their own 
policies and seek alternative sources of funding because Science Foundation 
Ireland or the Health Research Board are unable to provide any funding until 
there is legislation.7 Relying on local University Academic guidelines may result 
in a fragmented legal structure. The absence of legislation affects the quality of 
research by a) increasing the potential for abuse, b) negatively impacting on 
potential international investment and c) collaboration repelling foreign scientific 
investment and biotech companies. Indeed Irelands lack of cohesive regulation 
impacts negatively on public trust resulting in a taboo type of research.  
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The moral status of the embryo will inevitably garner varying opinion in society 
as factors such as personal beliefs, culture, local politics and of course religion 
influence opinion. This is reflective within the EU and the different legislations 
that exist today. Christian faiths have a conservative opinion where the embryo 
has the same status of a human at the time of conception. This is in contrast 
with the Islamic faith and Jewish law of Halacha where the embryo does not 
have human status prior to 40 days.8 Legislation provides an ethical structure 
within scientists can effectively and most importantly safely work. 
 
5.2 Future work 
 
Specifically Ireland needs to prioritise legislating for hESCR because a 
European country with no specific legislation is regressive, incomprehensible 
and irresponsible. Ireland should have a comprehensive system and regulatory 
body similar to the UK. Guidelines from the Irish Medical Council are not 
sufficient and adequate. These are guidelines for doctors only, not scientists. 
The Bill on Assisted Human Reproduction needs to be expedited by the 
Government as a draft should have been published this summer.4 Ireland is one 
of the few countries in Europe which provides assisted human reproduction 
services without a regulatory framework exposing both patients and doctors to 
vulnerable and unsafe situations.    
 
While scientists have created alternative techniques such as reprogramming of 
somatic cells or somatic nuclear transfer to circumvent the ethical and legal 
issues associated with destroying the human embryo, these techniques pose 
their own ethical issues and debate.9 Instead of regarding these as a 
replacement for hESCR, they should be used to complement it and help 
researchers to fine tune their existing techniques thus improving overall patient 
safety. The future of combining iPSC technology with gene editing is a possible 
therapeutic opportunity. 
 
Regarding gene editing, there should be more discussion in the public domain 
as we are “on the cusp of a gene editing revolution” but without any public 
awareness or acceptance yet.10 Despite what this exciting technology can 
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promise and the enthusiasm it creates amongst the scientific community, the 
general public may not be prepared to accept the pace of progress just yet. 
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